title: Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization.
abstract: We assessed the hematopoietic recovery and transplantation-related mortality (TRM) of patients who had failed peripheral blood stem cell mobilization and subsequently received high-dose chemotherapy supported by granulocyte colony-stimulating factor (G-CSF)-primed bone marrow (BM). Studied were 86 heavily pretreated consecutive patients with acute leukemia (n = 21), refractory/relapsed non-Hodgkin lymphoma (n = 41) and Hodgkin disease (n = 17), and multiple myeloma (n = 7). There were 78 patients who showed insufficient mobilization of CD34+ cells (< 10 cells/microL), whereas 8 patients collected less than 1 x 106 CD34+ cells/kg. BM was primed in vivo for 3 days with 15 to 16 microg/kg of subcutaneous G-CSF. Median numbers of nucleated cells, colony-forming unit cells (CFU-Cs), and CD34+ cells per kilogram harvested were 3.5 x 10(8), 3.72 x 10(4), and 0.82 x 10(6), respectively. Following myeloablative chemotherapy, median times to achieve a granulocyte count higher than 0.5 x 10(9)/L and an unsupported platelet count higher than 20 and 50 x 10(9)/L were 13 (range, 8-24), 15 (range, 12-75), and 22 (range, 12-180) days, respectively, for lymphoma/myeloma patients and 23 (range, 13-53), 52 (range, 40-120), and 90 (range, 46-207) days, respectively, for leukemia patients. Median times to hospital discharge after transplantation were 17 (range, 12-40) and 27 (range, 14-39) days for lymphoma/myeloma and acute leukemia patients, respectively. TRM was 4.6%, whereas 15 patients died of disease. G-CSF-primed BM induces effective multilineage hematopoietic recovery after high-dose chemotherapy and can be safely used in patients with poor stem cell mobilization.
authors.affiliation: Institute of Hematology and Medical Oncology "Seràgnoli" Via Massarenti, 9, 40100 Bologna, Italy. rmlemoli@med.unibo.it
authors.forename: Roberto M
authors.initials: RM
authors.lastname: Lemoli
authors.forename: Antonio
authors.initials: A
authors.lastname: de Vivo
authors.forename: Daniela
authors.initials: D
authors.lastname: Damiani
authors.forename: Alessandro
authors.initials: A
authors.lastname: Isidori
authors.forename: Monica
authors.initials: M
authors.lastname: Tani
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bonini
authors.forename: Claudia
authors.initials: C
authors.lastname: Cellini
authors.forename: Antonio
authors.initials: A
authors.lastname: Curti
authors.forename: Luigi
authors.initials: L
authors.lastname: Gugliotta
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Visani
authors.forename: Renato
authors.initials: R
authors.lastname: Fanin
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001853:Bone Marrow / Q000187:drug effects; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006410:Hematopoiesis / Q000187:drug effects; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy; D006801:Humans; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D008223:Lymphoma / Q000401:mortality / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy; D011446:Prospective Studies; D016019:Survival Analysis; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor